Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

olprinone

Known as: 1,2-dihydro-6-methyl-2-oxo-5-(imidazo(1,2-a)pyridin-6-yl)-3-pyridinecarbonitrile 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Endothelial barrier function is an essential and tightly regulated process that ensures proper compartmentalization of the… Expand
  • figure 1
  • figure 2
2012
2012
Olprinone, a specific phosphodiesterase III inhibitor, and corforsin daropate, a direct adenylate cyclase activator, are now… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2008
2008
PURPOSE Acute respiratory distress syndrome is characterized by neutrophil accumulation in the lungs and the activation of… Expand
2003
2003
Cerebral blood flow (CBF) is reduced in heart failure (HF). For the treatment of acute HF, a phosphodiesterase-3 inhibitor… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
Review
2002
Review
2002
Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive… Expand
Highly Cited
2001
Highly Cited
2001
Background—Phosphodiesterase III inhibitors (PDEIII-Is) improve the hemodynamic status of heart failure via inotropic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2000
2000
Objective: To measure the hepatic venous oxygen saturation in patients after cardiac surgery and to compare the effects of… Expand
2000
2000
Background: Increasing evidence indicates that amrinone, a phosphodiesterase fraction III (PDE‐III) inhibitor, has relative… Expand
Highly Cited
1999
Highly Cited
1999
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the… Expand
1998
1998
We investigated the inotropic effect of SCH00013 (4, 5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]-1,2,5, 6-tetrahydropyrido… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4